Skip to content
PeptideFactSheets

Peptide · Fact sheet

Thymosin beta-4

Also known as Tβ4 · TB4 · full-length thymosin beta-4 · TB-500 (fragment marketed online)

Thymosin beta-4 is a naturally occurring peptide involved in cell movement and tissue processes. Experimental full-length products and the TB-500 fragment marketed online should not be treated as proven or interchangeable therapies.

Not FDA approvedMostly animal or lab research
Muscle & recoverySkin & hair

What is Thymosin beta-4?

Thymosin beta-4 is present in many tissues and has roles involving actin, cell movement, inflammation, and repair signaling.

TB-500 commonly refers to a shorter fragment marketed online. Evidence about full-length thymosin beta-4 cannot automatically be applied to that fragment or to an unverified product.

Benefits people look for

It is discussed for injury recovery, wound healing, heart repair, eye conditions, and athletic performance.

Much of the enthusiasm comes from mechanistic or preclinical research rather than proven clinical outcomes.

What the evidence supports

  • Preclinical research suggests roles in cell migration, blood-vessel formation, and tissue repair.
  • Early studies do not establish a general injury-recovery or athletic-performance treatment.
All research areas
  • Tissue and wound repair
  • Corneal healing
  • Cardiac repair
  • Inflammation
  • Cell migration
  • Topical and systemic tissue-repair applications in research settings

Anecdotal reports & lived experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.

Reported benefit · personal report

Less knee pain during combined exposure

One person attributed a gradual reduction in longstanding knee pain to products labeled BPC-157 and TB-500 used together.

Two products were used, with no control group or independent assessment of healing. The account cannot separate their effects. TB-500 product labeling does not verify equivalence to full-length thymosin beta-4.

Read the knee-pain report ↗
Reported side effect · personal report

Severe anxiety, sleeplessness and chest tightness

A different person reported these symptoms after exposure to products labeled BPC-157 and TB-500, including seeking hospital assessment.

Combined exposure and unverified product identity prevent attribution to either substance. This is a personal report, not a confirmed drug reaction or an estimate of risk.

Read the adverse-experience report ↗

Side effects & risks

  • FDA notes potential immune reactions, aggregation, peptide impurities, and a lack of identified human exposure data for the TB-500 fragment in drug products.
  • Systemic effects and long-term consequences are insufficiently understood.
  • Online products add identity, purity, sterility, and labeling uncertainty.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research: how strong is it?

Mostly animal or lab research

There are early human studies in selected areas, but the broad recovery claims seen online are supported mainly by preclinical evidence.

Selected research to read

FDA approval & research status

No thymosin beta-4 or TB-500 product is FDA approved for consumer recovery or performance uses. FDA has specifically described evidence gaps and potential risks for the thymosin beta-4 fragment used in compounding.

No FDA-approved use is documented in the records summarized on this page.

Ophthalmic Phase 3 studies completed

RGN-259, a thymosin beta-4 ophthalmic product candidate, has completed Phase 3 dry-eye studies. No thymosin beta-4 or TB-500 product is FDA approved.

This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.

What we still don’t know

  • Whether effects in models translate into improved human recovery
  • How full-length thymosin beta-4 differs clinically from marketed fragments
  • Long-term safety and effects on abnormal blood-vessel or cell growth
  • Whether research products and products marketed online have the same identity and manufacturing quality

The takeaway

Thymosin beta-4 is scientifically interesting, but online recovery claims run ahead of clinical proof. Full-length peptide, fragments, and marketed products are not automatically equivalent.

Sources & further reading

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. 1
    fdaFDA: bulk substances that may present significant safety risks

    FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.

  2. 2
    clinical trialsClinicalTrials.gov: RGN-259 ARISE-2 dry eye study

    Registry record for an ophthalmic thymosin beta-4-related study.

  3. 3
    clinical trialsClinicalTrials.gov: RGN-259 ARISE-3 dry eye study

    Registry record for an additional ophthalmic thymosin beta-4-related study.

  4. 4
    pubmedThymosin beta-4 and corneal inflammation review

    Peer-reviewed review discussing thymosin beta-4 in corneal wound healing and inflammation.

How we assess sources · Suggest a correction